Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board

Inhibitors of the sodium-glucose cotransporter type 2 (SGLT2i) are a modern class of antihyperglycemic drugs with an insulin-independent mechanism of action. Due to its ability to effectively lower blood glucose levels, improve a number of other cardiometabolic parameters (body weight, blood pressur...

Full description

Bibliographic Details
Main Authors: M. V. Shestakova, A. S. Ametov, M. B. Antsiferov, T. P. Bardymova, F. V. Valeeva, G. R. Galstyan, T. Yu. Demidova, I. A. Karpova, T. P. Kiseleva, A. Yu. Mayorov, A. M. Mkrtumyan, S. V. Nedogoda, N. А. Petunina, L. A. Ruyatkina, L. A. Suplotova, O. Yu. Sukhareva, V. V. Fadeev, M. S. Shamkhalova
Format: Article
Language:English
Published: Endocrinology Research Centre 2022-01-01
Series:Сахарный диабет
Subjects:
canagliflozin
sglt2i
sglt1
type 2 diabetes mellitus
cardiovascular risks
renal risks
safety
Online Access:https://www.dia-endojournals.ru/jour/article/view/12848

Internet

https://www.dia-endojournals.ru/jour/article/view/12848

Similar Items